R. Tilmont

Treatment with temozolomide and ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL)

F. Morschhauser, E. Boyle, L. Renaud, 2020, European journal of haematology.

Impact of Defibrotide in the Prevention of Acute Graft-Versus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation

I. Yakoub-Agha, N. Simon, P. Odou, 2022, The Annals of pharmacotherapy.

Role of TNFRSF17 and GPRC5D Structural and Point Mutations in Resistance to Targeted Immunotherapies in Multiple Myeloma (MM)

P. Neri, F. Maura, O. Landgren, 2022, Blood.

Safety and efficacy of nivolumab in patients who failed to achieve a complete remission after CD19-directed CAR T-cell therapy in diffuse large B cell lymphoma.

I. Yakoub-Agha, E. Alidjinou, F. Morschhauser, 2023, British Journal of Haematology.

Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMT.

J. Bourhis, I. Yakoub-Agha, D. Mclornan, 2023, Bone marrow transplantation.

Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma

A. Rosenwald, J. Keats, A. Krishnan, 2023, Nature Medicine.

ETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple Myeloma

J. Keats, S. Lonial, B. Barwick, 2023, Blood cancer discovery.